Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.42 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6228430 | 0.79 | FKBP5 (0.53) | NPC1RAB9AMEN1KMT2ATP53 | |
| SCHEMBL9106594 | 0.76 | PLK1 (0.54) | NPC1RAB9A | |
| SCHEMBL7976244 | 0.76 | GAA (0.45) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL6232375 | 0.76 | NPC1 (0.55) | NPC1RAB9AMEN1KMT2AMAOB | |
| SCHEMBL7583446 | 0.75 | KMT2A (0.50) | NPC1RAB9AMEN1KMT2ATP53 | |
| SCHEMBL7240252 | 0.72 | NPC1 (0.51) | NPC1RAB9AMEN1KMT2ATP53 | |
| SCHEMBL20507043 | 0.72 | CYP1A2 (0.40) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL2517773 | 0.72 | NR4A1 (0.48) | NPC1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL7578629 | 0.72 | RAB9A (0.54) | NPC1RAB9AMEN1KMT2ATP53 | |
| SCHEMBL12275191 | 0.71 | NPC1 (0.54) | NPC1RAB9AADORA3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900219-B2 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1513534-A2 | COMPOUNDS FOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20030220356-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003084544-A2 | COMPOUNDS DOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220356-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | NPC1 6/4885RAB9A 2138/4885ADORA3 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.